A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

Summary

This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.

Timeline

Start

2026-12

Primary completion

2026-12

Completion

2027-01

Outcome

Outcome not reported

Stopped: “The sponsor has decided to suspend study progress. Further implementation of the study is pending notification.”

Drugs

Indications